Clinical significance of miR-146a in gastric cancer cases

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4277-4284

  Kogo, Ryunosuke ^a,b   Mimori, Koshi ^a   Tanaka, Fumiaki ^a   Komune, Shizuo ^b   Mori, Masaki ^c  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MICRORNA; MICRORNA 146A; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; ENZYME REGULATION; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNET RING CARCINOMA; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 79960336510     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2866     Document Type: Article

References (32)

1. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1-9. (Pubitemid 36183309)
2. Sun P, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg 2009; 96:26-33.
3. Scartozzi M, Bittoni A, Pistelli M, Galizia E, Berardi R, Giampieri R, et al. Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. Cancer Treat Rev 2009;35:451-62.
4. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett 2008;266:99-115.
5. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66. (Pubitemid 44629897)
6. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353: 1793-801. (Pubitemid 41549891)
7. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61. (Pubitemid 43271657)
8. Li Y, Vandenboom TG, Wang Z, Kong D, Ali S, Philip PA, et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 2010;70:1486-95.
9. Navolanic PM, Steelman LS, McCubrey JA. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol 2003;22:237-52.
10. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118:257-62. (Pubitemid 41779062)
11. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008;27:5643-7.
12. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2008;105:7269-74. (Pubitemid 351754467)
13. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB. Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene 2007;26:7324-32. (Pubitemid 350115978)
14. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009;69:1279-83.
15. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 2008;14:417-24. (Pubitemid 351397806)
16. Xu B, Feng NH, Li PC, Tao J, Wu D, Zhang ZD, et al. A functional polymorphism in Pre-miR-146a gene is associated with prostate cancer risk and mature miR-146a expression in vivo. Prostate 2010;70:467-72.
17. Jazdzewski K, Liyanarachchi S, Swierniak M, Pachucki J, Ringel MD, Jarzab B, et al. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A 2009;106:1502-5.
18. Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 2008;29:1963-6.
19. Xu T, Zhu Y, Wei QK, Yuan Y, Zhou F, Ge YY, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 2008;29:2126-31.
20. A JGC. Japanese Classification of Gastric Carcinoma-2ndEnglish Edition. Gastric Cancer 1998;1:10-24.
21. Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer,and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 2011.
22. Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K, et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer 2007;121:33-8. (Pubitemid 46753848)
23. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45. (Pubitemid 17082655)
24. Li X, Zhang Y, Ding J, Wu K, Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010;59: 579-85.
25. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010;11:136-46.
26. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
27. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43. (Pubitemid 46021510)
28. Arkenau HT. Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol 2009;135:855-66.
29. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009;100:298-304.
30. Lee BL, Lee HS, Jung J, Cho SJ, Chung HY, Kim WH, et al. Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin Cancer Res 2005;11:2518-25. (Pubitemid 40569448)
31. Yamanaka N, Morisaki T, Nakashima H, Tasaki A, Kubo M, Kuga H, et al. Interleukin 1beta enhances invasive ability of gastric carcinoma through nuclear factor-kappaB activation. Clin Cancer Res 2004;10:1853-9. (Pubitemid 38435577)
32. Duan R, Pak C, Jin P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet 2007;16:1124-31. (Pubitemid 47062732)